MLEC — Moolec Science S.A.

Summary of Moolec Science Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Normalized Revenues: Increased to $5.8 million in FY2024 from approximately $1 million in FY2023, attributed to the consolidation of the soy product ingredient business.
• Cost of Sales: Rose to $4.5 million from nearly $1 million in FY2023, aligning with revenue growth.
• Operating Expenses: SG&A and R&D expenses increased to $9.3 million from $6.2 million, mainly due to non-cash items and the consolidation of the soy ingredient business.
• Cash Utilization: Increased to $9.3 million from $7.5 million in FY2023, with a cash position of approximately $5.4 million as of Q4 2024.
• Convertible Note: Issued to BIOX for the purchase of 15,000 tons of HB4 soybean, securing raw material needs until December 2025.

2. Strategic Updates and Business Highlights

• Milestones Achieved:
  • USDA approval for Piggy Sooy, marking a significant regulatory achievement.
  • Established a fully operational molecular biology lab (Moolabs) in Texas.
  • Initiated field trials for Piggy Sooy in multiple states and began planting for Glaso production.
  • Secured an offtake agreement with a major global CPG company for Glaso, expected to generate revenue in FY2025.
• Product Development: Continued focus on R&D for new proteins and molecular products, with plans to enhance operational efficiency and quality control.

3. Forward Guidance and Outlook

• Commercialization Plans: Expecting Glaso to contribute approximately 15% of total revenue in FY2025, with gradual growth anticipated.
• Operational Focus: Plans to optimize yields and enhance product quality, while expanding sales and marketing efforts.
• Regulatory Pathway: Commitment to advancing regulatory approvals for Piggy Sooy, with no anticipated delays in the commercialization timeline for 2027-2028.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Rising SG&A and R&D costs could impact profitability if not managed effectively.
• Cash Utilization: Continued high cash burn raises concerns about liquidity and funding for future operations.
• Market Awareness: Limited public understanding of plant molecular farming technology may hinder broader market adoption and investor interest.

5. Notable Q&A Insights

• Offtake Agreement Details: The agreement for Glaso is a three-year contract with a major CPG company focused on pet food applications, with expectations for significant revenue growth.
• Market Positioning: Glaso is positioned as a premium product with higher GLA concentration compared to competitors, which may enhance its market appeal.
• Future Collaborations: Discussions with other potential customers are ongoing, with optimism about securing additional contracts in the near future.
• Bunge Collaboration: The R&D partnership with Bunge aims to improve safflower varieties for both biofuel and bioreactor applications, highlighting potential for future growth in multiple markets.

Overall, Moolec Science demonstrated strong progress in FY2024 with significant milestones in product development and regulatory approvals, although challenges related to rising costs and market awareness remain. The outlook for FY2025 appears optimistic with expected revenue growth from new product launches.